...
机译:P1.13-43患有Her2突变肺癌患者Ado-Trastuzumab Omtansine的分子和成像预测因子:探索性2阶段试验
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Nantomics Rockville/MD/US;
Nantomics Rockville/MD/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
King'S College London London/GB;
King'S College London London/GB;
King'S College London London/GB;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
机译:P1.13-43患有Her2突变肺癌患者Ado-Trastuzumab Omtansine的分子和成像预测因子:探索性2阶段试验
机译:患有Her2-突变肺癌患者的Ado-Trastuzumab Omtansine:II期篮子试验结果
机译:OA 14.05阶段2篮子试验Ado-Trastuzumab Omtansine患者2患者2患者患者2突变体或扩增肺癌
机译:临床,剂量相关和影像学特征的结合可帮助预测肺癌患者放射诱发的正常组织毒性-使用机器学习技术的计算机模拟试验
机译:Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
机译:Ado-曲妥珠单抗Emtansine治疗HER2突变型肺癌的患者:II期临床试验结果
机译:患有Her2-突变肺癌患者的Ado-Trastuzumab Omtansine:II期篮子试验结果